In conclusion, the results obtained indicate that Egr1 is a critical tumor suppressor of BCR-ABL driven chronic myelogenous leukemia providing the impetus to further investigate the role of Egr1 and explore its potential as a therapeutic target in other cancers. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.